Recent Articles

• 
  Medical / Research

  Killer Cells Track, Attack Cancer With Higher Accuracy

  Photo provided by Korea Research Institute of Chemical Technology The performance of a next-generation gene cell therapy, the chimeric antigen receptor (CAR) therapy—designed to directly locate and attack cancer cells—has been enhanced by a newly developed technology. CAR therapy is a treatment that

  2026.06.22
• 
  Global Business

  K-Bio Targets US Jackpot With New Drug Tech

  The world’s largest pharmaceutical and biotech exhibition, the “2026 BIO International Convention (BIO USA),” opened on the 22nd (local time) in San Diego, United States, and will continue for four days. BIO USA, organized by the Biotechnology Innovation Organization (BIO), marks its 33rd edition th

  2026.06.22
• 
  Diagnostics / Monitoring

  SCL Healthcare Wins U.S. Patent for Gene Test Predicting Metabolic Syndrome

  SCL Healthcare announced on the 18th that it has obtained a U.S. patent for a technology that predicts, through genetic testing, the risk of high blood expression of ceramide—regarded as a key cause of metabolic syndrome.The patented technology uses 12 single nucleotide polymorphism (SNP) markers id

  2026.06.18
• 
  AI Healthcare

  Celltrion Marks 17th Year at BIO USA, Showcases Pipeline

  Celltrion BioUSA booth. Provided by Celltrion Celltrion will showcase its artificial intelligence (AI)-based drug development technology, antibody-drug conjugate (ADC) and multi-specific antibody pipelines at the “2026 BIO International Convention (BIO USA),” the world’s largest bioindustry event. T

  2026.06.18
• 
  AI Healthcare

  LG AI Research, D&D Pharmatech to Co-Develop Peptide Drug

  Woo-Hyung Lim, Head of LG AI Research Institute (left), and Seulgi Lee, CEO of D&D Pharmatech, take a commemorative photo after signing the main contract for the joint development of next-generation peptide drugs. Provided by LG LG is moving to secure leadership in the artificial intelligence (AI) b

  2026.06.17
• 
  Bioprocessing

  Chungbuk National Team Mass-Produces 150-Year Ginseng Roots

  Chungbuk National University research team has succeeded in mass-producing cultured roots using a 150-year-old wild ginseng plant. The research team led by Professor Park So-young of the Department of Horticultural Science at Chungbuk National University unveiled the mass production site of cultured

  2026.06.17
• 
  Medical / Drug Development

  Hanmi Unveils First Glimpse of Obesity Drug HM500197

  Senior Researcher Seon-myung Lee, Team Leader of Hanmi Pharm’s Future Growth Division, presents the latest research results on HM17321, the world’s first muscle-increasing obesity treatment, at the American Diabetes Association (ADA 2026). Courtesy of Hanmi Pharm Hanmi Pharm, which recently drew att

  2026.06.16
• 
  Medical / Clinical Case

  GC Wellbeing’s Liver Drug Linek IV Trial Succeeds

  GC Green Cross Wellbeing announced on the 16th that it has obtained top-line results demonstrating that the high-dose intravenous drip regimen of its chronic liver disease treatment “LIVACT Injection (LIVACT)” met the primary endpoint in a Phase 3 clinical trial. The intravenous drip regimen refers

  2026.06.16
• 
  Global Business

  SK Plasma Breaks Ground on Türkiye Plant, Targets 2030

  On the 11th (local time), at the groundbreaking ceremony for SK Plasma’s plasma fractionation plant in Türkiye held at the Presidential Complex, SK Chemicals President Ahn Jae-hyun greets President Recep Tayyip Erdoğan of Türkiye. In the middle is Fatma Meriç, President of Türkiye. SK Plasma will bu

  2026.06.15
• 
  Clinical Trial

  Yuhan Announces Phase 1b Allergy Drug Data, Moves to Global Phase 2

  Yuhan Corporation Central Research Institute. Provided by Yuhan Corporation Yuhan Corporation announced on the 15th that in a Phase 1b clinical trial of its candidate drug for allergic diseases, “Lecigercept,” it confirmed the safety of repeated administration and the sustainability of its inhibitor

  2026.06.15